发明名称 |
Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation |
摘要 |
A method is provided of identifying compounds for use in a pharmaceutical composition having an anti-viral effect against CXCR4-dependent HIV activity comprising: providing a first aliquot of CXCR-4-expressing GH-Tg cells; contacting said first aliquot with HIV particles; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with a test ligand; contacting said second aliquot with HIV particles; and isolating virus from said first and said second aliquot of cells, wherein a decrease in the ability to isolate virus from said second aliquot cells indicates said test ligand possess anti-viral activity against HIV. Also provided is a method of identifying compounds for use in a pharmaceutical composition having a therapeutic effect against a disease involving CXCR4-dependent chemotaxis comprising providing a first aliquot CXCR4-expressing GH-Tg cells; contacting said first aliquot with CXCL12; measuring a first migration indes; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with CXCL12; contacting said second aliquot with a test ligand; measuring a second migration index; and determing a therapeutic potential. In addition, compounds for us in a pharmaceutical composition having a therapeutic effect against a SOCS3 inhibitable disease are identified by a method comprising: providing a first cell having at least one chemokine receptor expressed thereon, said first cell having been transfected with at least one SOCS construct; contacting said first cell with at least one chemokine, measuring a first migration index; providing a second cell having at least one chemokine receptor expressed thereon, said second cell having been transfected with at least one SOCS construct; contacting said second cell with at least one chemokine; measuring a second migration index; and determining a therapeutic potential subjects having a disease associated with CXCR4-dependent HIV are treated by administering to said subject a therapeutically anti-viral effective amount of a compound that induces the expression of SOCS3 and a pharmaceutically acceptable carrier.
|
申请公布号 |
US2005221287(A1) |
申请公布日期 |
2005.10.06 |
申请号 |
US20050500558 |
申请日期 |
2005.04.04 |
申请人 |
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS PHARMACIA SPAIN, S.A. |
发明人 |
MARTINEZ-ALONZO CARLOS;MELLADO MARIO;RODRIGUES-FRADE JOSE |
分类号 |
G01N33/50;A01K67/027;A61K38/00;A61K45/00;A61P1/04;A61P1/16;A61P7/00;A61P11/00;A61P11/06;A61P13/12;A61P17/00;A61P17/06;A61P19/02;A61P25/00;A61P31/18;A61P37/08;A61P43/00;C12N15/09;C12Q1/02;C12Q1/70;G01N33/15;G01N33/569;G01N33/68;G01N33/74;(IPC1-7):C12Q1/70 |
主分类号 |
G01N33/50 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|